The first experience with Angiovit in the combination treatment of acute COVID-19 infection
Authors:
Open Access
- 25 June 2020
- journal article
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 12 (3) , 82-86
Abstract
The first experience with Angiovit in the combination treatment of acute COVID-19 infectionKeywords
This publication has 16 references indexed in Scilit:
- Hispidin and Lepidine E: Two Natural Compounds and Folic Acid as Potential Inhibitors of 2019-novel Coronavirus Main Protease (2019-nCoVMpro), Molecular Docking and SAR StudyCurrent Computer-Aided Drug Design, 2021
- Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosisClinica Chimica Acta, 2020
- Predictors for imaging progression on chest CT from coronavirus disease 2019 (COVID-19) patientsAging, 2020
- Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infectionFrontiers of Medicine, 2020
- Hyperhomocysteinemia and endothelial dysfunction in patients with cerebral vascular and autoimmune diseasesS.S. Korsakov Journal of Neurology and Psychiatry, 2019
- Homocysteine directly interacts and activates the angiotensin II type I receptor to aggravate vascular injuryNature Communications, 2018
- Homocysteine to Hydrogen Sulfide or HypertensionCell Biochemistry and Biophysics, 2010
- The activity of erythrocyte and brain Na+/K+ and Mg2+-ATPases in rats subjected to acute homocysteine and homocysteine thiolactone administrationMolecular and Cellular Biochemistry, 2009
- High levels of homocysteine inhibit lysyl oxidase (LOX) and downregulate LOX expression in vascular endothelial cellsAtherosclerosis, 2004
- Focus on Homocysteine and the Vitamins2002